SOURCE-LINKED STUDY SUMMARY
Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
Abstract summarizedQuality not appraised
- What was studied
- Researchers used physician-checked automated extraction of US clinical notes from 2020–2026 to describe BPC-157 use and reported outcomes.
- Who / model studied
- There were 1,039 documented users. Responses were recorded for 354; use averaged 2.2 months among the 130 with documented duration.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Among users with recorded responses, 79% reported improvement and 5% worsening. Neuropsychiatric, injection-site and digestive adverse events were also recorded.
- Limitations & context
- Response direction was missing for 65.9%. Co-treatments, reporting biases and imperfect extraction prevent conclusions about effectiveness. Adverse events were probably under-reported.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.20944/preprints202609.0501.v1